img

Global Drug-Resistant Tuberculosis Treatment Market Insights, Forecast to 2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Drug-Resistant Tuberculosis Treatment Market Insights, Forecast to 2034

Market Analysis and InsightsGlobal Drug-Resistant Tuberculosis Treatment Market
The global Drug-Resistant Tuberculosis Treatment market is projected to grow from US$ million in 2024 to US$ million by 2034, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Drug-Resistant Tuberculosis Treatment is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The China market for Drug-Resistant Tuberculosis Treatment is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The Europe market for Drug-Resistant Tuberculosis Treatment is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The global key companies of Drug-Resistant Tuberculosis Treatment include Sanofi, Novartis AG, Endo International plc, CMP Pharma, STI Pharma LLC, Akorn Incorporated, Lupin, Johnson & Johnson Services Inc. and Macleods Pharmaceuticals Ltd, etc. in 2022, the global top five players had a share approximately % in terms of revenue.
Report Includes
This report presents an overview of global market for Drug-Resistant Tuberculosis Treatment market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2024, and projections of CAGR through 2034.
This report researches the key producers of Drug-Resistant Tuberculosis Treatment, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Drug-Resistant Tuberculosis Treatment, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Drug-Resistant Tuberculosis Treatment revenue, market share and industry ranking of main companies, data from 2018 to 2024. Identification of the major stakeholders in the global Drug-Resistant Tuberculosis Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2034. Evaluation and forecast the market size for Drug-Resistant Tuberculosis Treatment revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Sanofi, Novartis AG, Endo International plc, CMP Pharma, STI Pharma LLC, Akorn Incorporated, Lupin, Johnson & Johnson Services Inc. and Macleods Pharmaceuticals Ltd, etc.



By Company


Sanofi
Novartis AG
Endo International plc
CMP Pharma
STI Pharma LLC
Akorn Incorporated
Lupin
Johnson & Johnson Services Inc.
Macleods Pharmaceuticals Ltd
Pfizer Inc
Hikma Pharmaceuticals PLC
Lannett
Mylan N.V.
Teva Pharmaceutical Industries Ltd
Fresenius Kabi AG
Segment by Type
First-Line Anti-TB Drugs
Second-Line Anti-TB Drugs
Others

Segment by Application


Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East, Africa, and Latin America
Turkey
Saudi Arabia
UAE
Rest of MEA

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Revenue of Drug-Resistant Tuberculosis Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3Detailed analysis of Drug-Resistant Tuberculosis Treatment companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8China by type and by application revenue for each segment.
Chapter 9Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Drug-Resistant Tuberculosis Treatment revenue, gross margin, and recent development, etc.
Chapter 12Analyst's Viewpoints/Conclusions

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Drug-Resistant Tuberculosis Treatment Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 First-Line Anti-TB Drugs
1.2.3 Second-Line Anti-TB Drugs
1.2.4 Others
1.3 Market by Application
1.3.1 Global Drug-Resistant Tuberculosis Treatment Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Hospital Pharmacy
1.3.3 Online Pharmacy
1.3.4 Retail Pharmacy
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Drug-Resistant Tuberculosis Treatment Market Perspective (2018-2034)
2.2 Global Drug-Resistant Tuberculosis Treatment Growth Trends by Region
2.2.1 Drug-Resistant Tuberculosis Treatment Market Size by Region: 2018 VS 2022 VS 2034
2.2.2 Drug-Resistant Tuberculosis Treatment Historic Market Size by Region (2018-2024)
2.2.3 Drug-Resistant Tuberculosis Treatment Forecasted Market Size by Region (2024-2034)
2.3 Drug-Resistant Tuberculosis Treatment Market Dynamics
2.3.1 Drug-Resistant Tuberculosis Treatment Industry Trends
2.3.2 Drug-Resistant Tuberculosis Treatment Market Drivers
2.3.3 Drug-Resistant Tuberculosis Treatment Market Challenges
2.3.4 Drug-Resistant Tuberculosis Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Drug-Resistant Tuberculosis Treatment by Players
3.1.1 Global Drug-Resistant Tuberculosis Treatment Revenue by Players (2018-2024)
3.1.2 Global Drug-Resistant Tuberculosis Treatment Revenue Market Share by Players (2018-2024)
3.2 Global Drug-Resistant Tuberculosis Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Drug-Resistant Tuberculosis Treatment, Ranking by Revenue, 2021 VS 2022 VS 2024
3.4 Global Drug-Resistant Tuberculosis Treatment Market Concentration Ratio
3.4.1 Global Drug-Resistant Tuberculosis Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Drug-Resistant Tuberculosis Treatment Revenue in 2022
3.5 Global Key Players of Drug-Resistant Tuberculosis Treatment Head office and Area Served
3.6 Global Key Players of Drug-Resistant Tuberculosis Treatment, Product and Application
3.7 Global Key Players of Drug-Resistant Tuberculosis Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Drug-Resistant Tuberculosis Treatment Breakdown Data by Type
4.1 Global Drug-Resistant Tuberculosis Treatment Historic Market Size by Type (2018-2024)
4.2 Global Drug-Resistant Tuberculosis Treatment Forecasted Market Size by Type (2024-2034)
5 Drug-Resistant Tuberculosis Treatment Breakdown Data by Application
5.1 Global Drug-Resistant Tuberculosis Treatment Historic Market Size by Application (2018-2024)
5.2 Global Drug-Resistant Tuberculosis Treatment Forecasted Market Size by Application (2024-2034)
6 North America
6.1 North America Drug-Resistant Tuberculosis Treatment Market Size (2018-2034)
6.2 North America Drug-Resistant Tuberculosis Treatment Market Size by Type
6.2.1 North America Drug-Resistant Tuberculosis Treatment Market Size by Type (2018-2024)
6.2.2 North America Drug-Resistant Tuberculosis Treatment Market Size by Type (2024-2034)
6.2.3 North America Drug-Resistant Tuberculosis Treatment Market Share by Type (2018-2034)
6.3 North America Drug-Resistant Tuberculosis Treatment Market Size by Application
6.3.1 North America Drug-Resistant Tuberculosis Treatment Market Size by Application (2018-2024)
6.3.2 North America Drug-Resistant Tuberculosis Treatment Market Size by Application (2024-2034)
6.3.3 North America Drug-Resistant Tuberculosis Treatment Market Share by Application (2018-2034)
6.4 North America Drug-Resistant Tuberculosis Treatment Market Size by Country
6.4.1 North America Drug-Resistant Tuberculosis Treatment Market Size by Country: 2018 VS 2022 VS 2034
6.4.2 North America Drug-Resistant Tuberculosis Treatment Market Size by Country (2018-2024)
6.4.3 North America Drug-Resistant Tuberculosis Treatment Market Size by Country (2024-2034)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Drug-Resistant Tuberculosis Treatment Market Size (2018-2034)
7.2 Europe Drug-Resistant Tuberculosis Treatment Market Size by Type
7.2.1 Europe Drug-Resistant Tuberculosis Treatment Market Size by Type (2018-2024)
7.2.2 Europe Drug-Resistant Tuberculosis Treatment Market Size by Type (2024-2034)
7.2.3 Europe Drug-Resistant Tuberculosis Treatment Market Share by Type (2018-2034)
7.3 Europe Drug-Resistant Tuberculosis Treatment Market Size by Application
7.3.1 Europe Drug-Resistant Tuberculosis Treatment Market Size by Application (2018-2024)
7.3.2 Europe Drug-Resistant Tuberculosis Treatment Market Size by Application (2024-2034)
7.3.3 Europe Drug-Resistant Tuberculosis Treatment Market Share by Application (2018-2034)
7.4 Europe Drug-Resistant Tuberculosis Treatment Market Size by Country
7.4.1 Europe Drug-Resistant Tuberculosis Treatment Market Size by Country: 2018 VS 2022 VS 2034
7.4.2 Europe Drug-Resistant Tuberculosis Treatment Market Size by Country (2018-2024)
7.4.3 Europe Drug-Resistant Tuberculosis Treatment Market Size by Country (2024-2034)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Drug-Resistant Tuberculosis Treatment Market Size (2018-2034)
8.2 China Drug-Resistant Tuberculosis Treatment Market Size by Type
8.2.1 China Drug-Resistant Tuberculosis Treatment Market Size by Type (2018-2024)
8.2.2 China Drug-Resistant Tuberculosis Treatment Market Size by Type (2024-2034)
8.2.3 China Drug-Resistant Tuberculosis Treatment Market Share by Type (2018-2034)
8.3 China Drug-Resistant Tuberculosis Treatment Market Size by Application
8.3.1 China Drug-Resistant Tuberculosis Treatment Market Size by Application (2018-2024)
8.3.2 China Drug-Resistant Tuberculosis Treatment Market Size by Application (2024-2034)
8.3.3 China Drug-Resistant Tuberculosis Treatment Market Share by Application (2018-2034)
9 Asia (excluding China)
9.1 Asia Drug-Resistant Tuberculosis Treatment Market Size (2018-2034)
9.2 Asia Drug-Resistant Tuberculosis Treatment Market Size by Type
9.2.1 Asia Drug-Resistant Tuberculosis Treatment Market Size by Type (2018-2024)
9.2.2 Asia Drug-Resistant Tuberculosis Treatment Market Size by Type (2024-2034)
9.2.3 Asia Drug-Resistant Tuberculosis Treatment Market Share by Type (2018-2034)
9.3 Asia Drug-Resistant Tuberculosis Treatment Market Size by Application
9.3.1 Asia Drug-Resistant Tuberculosis Treatment Market Size by Application (2018-2024)
9.3.2 Asia Drug-Resistant Tuberculosis Treatment Market Size by Application (2024-2034)
9.3.3 Asia Drug-Resistant Tuberculosis Treatment Market Share by Application (2018-2034)
9.4 Asia Drug-Resistant Tuberculosis Treatment Market Size by Region
9.4.1 Asia Drug-Resistant Tuberculosis Treatment Market Size by Region: 2018 VS 2022 VS 2034
9.4.2 Asia Drug-Resistant Tuberculosis Treatment Market Size by Region (2018-2024)
9.4.3 Asia Drug-Resistant Tuberculosis Treatment Market Size by Region (2024-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Drug-Resistant Tuberculosis Treatment Market Size (2018-2034)
10.2 Middle East, Africa, and Latin America Drug-Resistant Tuberculosis Treatment Market Size by Type
10.2.1 Middle East, Africa, and Latin America Drug-Resistant Tuberculosis Treatment Market Size by Type (2018-2024)
10.2.2 Middle East, Africa, and Latin America Drug-Resistant Tuberculosis Treatment Market Size by Type (2024-2034)
10.2.3 Middle East, Africa, and Latin America Drug-Resistant Tuberculosis Treatment Market Share by Type (2018-2034)
10.3 Middle East, Africa, and Latin America Drug-Resistant Tuberculosis Treatment Market Size by Application
10.3.1 Middle East, Africa, and Latin America Drug-Resistant Tuberculosis Treatment Market Size by Application (2018-2024)
10.3.2 Middle East, Africa, and Latin America Drug-Resistant Tuberculosis Treatment Market Size by Application (2024-2034)
10.3.3 Middle East, Africa, and Latin America Drug-Resistant Tuberculosis Treatment Market Share by Application (2018-2034)
10.4 Middle East, Africa, and Latin America Drug-Resistant Tuberculosis Treatment Market Size by Country
10.4.1 Middle East, Africa, and Latin America Drug-Resistant Tuberculosis Treatment Market Size by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa, and Latin America Drug-Resistant Tuberculosis Treatment Market Size by Country (2018-2024)
10.4.3 Middle East, Africa, and Latin America Drug-Resistant Tuberculosis Treatment Market Size by Country (2024-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Sanofi
11.1.1 Sanofi Company Details
11.1.2 Sanofi Business Overview
11.1.3 Sanofi Drug-Resistant Tuberculosis Treatment Introduction
11.1.4 Sanofi Revenue in Drug-Resistant Tuberculosis Treatment Business (2018-2024)
11.1.5 Sanofi Recent Developments
11.2 Novartis AG
11.2.1 Novartis AG Company Details
11.2.2 Novartis AG Business Overview
11.2.3 Novartis AG Drug-Resistant Tuberculosis Treatment Introduction
11.2.4 Novartis AG Revenue in Drug-Resistant Tuberculosis Treatment Business (2018-2024)
11.2.5 Novartis AG Recent Developments
11.3 Endo International plc
11.3.1 Endo International plc Company Details
11.3.2 Endo International plc Business Overview
11.3.3 Endo International plc Drug-Resistant Tuberculosis Treatment Introduction
11.3.4 Endo International plc Revenue in Drug-Resistant Tuberculosis Treatment Business (2018-2024)
11.3.5 Endo International plc Recent Developments
11.4 CMP Pharma
11.4.1 CMP Pharma Company Details
11.4.2 CMP Pharma Business Overview
11.4.3 CMP Pharma Drug-Resistant Tuberculosis Treatment Introduction
11.4.4 CMP Pharma Revenue in Drug-Resistant Tuberculosis Treatment Business (2018-2024)
11.4.5 CMP Pharma Recent Developments
11.5 STI Pharma LLC
11.5.1 STI Pharma LLC Company Details
11.5.2 STI Pharma LLC Business Overview
11.5.3 STI Pharma LLC Drug-Resistant Tuberculosis Treatment Introduction
11.5.4 STI Pharma LLC Revenue in Drug-Resistant Tuberculosis Treatment Business (2018-2024)
11.5.5 STI Pharma LLC Recent Developments
11.6 Akorn Incorporated
11.6.1 Akorn Incorporated Company Details
11.6.2 Akorn Incorporated Business Overview
11.6.3 Akorn Incorporated Drug-Resistant Tuberculosis Treatment Introduction
11.6.4 Akorn Incorporated Revenue in Drug-Resistant Tuberculosis Treatment Business (2018-2024)
11.6.5 Akorn Incorporated Recent Developments
11.7 Lupin
11.7.1 Lupin Company Details
11.7.2 Lupin Business Overview
11.7.3 Lupin Drug-Resistant Tuberculosis Treatment Introduction
11.7.4 Lupin Revenue in Drug-Resistant Tuberculosis Treatment Business (2018-2024)
11.7.5 Lupin Recent Developments
11.8 Johnson & Johnson Services Inc.
11.8.1 Johnson & Johnson Services Inc. Company Details
11.8.2 Johnson & Johnson Services Inc. Business Overview
11.8.3 Johnson & Johnson Services Inc. Drug-Resistant Tuberculosis Treatment Introduction
11.8.4 Johnson & Johnson Services Inc. Revenue in Drug-Resistant Tuberculosis Treatment Business (2018-2024)
11.8.5 Johnson & Johnson Services Inc. Recent Developments
11.9 Macleods Pharmaceuticals Ltd
11.9.1 Macleods Pharmaceuticals Ltd Company Details
11.9.2 Macleods Pharmaceuticals Ltd Business Overview
11.9.3 Macleods Pharmaceuticals Ltd Drug-Resistant Tuberculosis Treatment Introduction
11.9.4 Macleods Pharmaceuticals Ltd Revenue in Drug-Resistant Tuberculosis Treatment Business (2018-2024)
11.9.5 Macleods Pharmaceuticals Ltd Recent Developments
11.10 Pfizer Inc
11.10.1 Pfizer Inc Company Details
11.10.2 Pfizer Inc Business Overview
11.10.3 Pfizer Inc Drug-Resistant Tuberculosis Treatment Introduction
11.10.4 Pfizer Inc Revenue in Drug-Resistant Tuberculosis Treatment Business (2018-2024)
11.10.5 Pfizer Inc Recent Developments
11.11 Hikma Pharmaceuticals PLC
11.11.1 Hikma Pharmaceuticals PLC Company Details
11.11.2 Hikma Pharmaceuticals PLC Business Overview
11.11.3 Hikma Pharmaceuticals PLC Drug-Resistant Tuberculosis Treatment Introduction
11.11.4 Hikma Pharmaceuticals PLC Revenue in Drug-Resistant Tuberculosis Treatment Business (2018-2024)
11.11.5 Hikma Pharmaceuticals PLC Recent Developments
11.12 Lannett
11.12.1 Lannett Company Details
11.12.2 Lannett Business Overview
11.12.3 Lannett Drug-Resistant Tuberculosis Treatment Introduction
11.12.4 Lannett Revenue in Drug-Resistant Tuberculosis Treatment Business (2018-2024)
11.12.5 Lannett Recent Developments
11.13 Mylan N.V.
11.13.1 Mylan N.V. Company Details
11.13.2 Mylan N.V. Business Overview
11.13.3 Mylan N.V. Drug-Resistant Tuberculosis Treatment Introduction
11.13.4 Mylan N.V. Revenue in Drug-Resistant Tuberculosis Treatment Business (2018-2024)
11.13.5 Mylan N.V. Recent Developments
11.14 Teva Pharmaceutical Industries Ltd
11.14.1 Teva Pharmaceutical Industries Ltd Company Details
11.14.2 Teva Pharmaceutical Industries Ltd Business Overview
11.14.3 Teva Pharmaceutical Industries Ltd Drug-Resistant Tuberculosis Treatment Introduction
11.14.4 Teva Pharmaceutical Industries Ltd Revenue in Drug-Resistant Tuberculosis Treatment Business (2018-2024)
11.14.5 Teva Pharmaceutical Industries Ltd Recent Developments
11.15 Fresenius Kabi AG
11.15.1 Fresenius Kabi AG Company Details
11.15.2 Fresenius Kabi AG Business Overview
11.15.3 Fresenius Kabi AG Drug-Resistant Tuberculosis Treatment Introduction
11.15.4 Fresenius Kabi AG Revenue in Drug-Resistant Tuberculosis Treatment Business (2018-2024)
11.15.5 Fresenius Kabi AG Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Drug-Resistant Tuberculosis Treatment Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2034
Table 2. Key Players of First-Line Anti-TB Drugs
Table 3. Key Players of Second-Line Anti-TB Drugs
Table 4. Key Players of Others
Table 5. Global Drug-Resistant Tuberculosis Treatment Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2034
Table 6. Global Drug-Resistant Tuberculosis Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2034
Table 7. Global Drug-Resistant Tuberculosis Treatment Market Size by Region (2018-2024) & (US$ Million)
Table 8. Global Drug-Resistant Tuberculosis Treatment Market Share by Region (2018-2024)
Table 9. Global Drug-Resistant Tuberculosis Treatment Forecasted Market Size by Region (2024-2034) & (US$ Million)
Table 10. Global Drug-Resistant Tuberculosis Treatment Market Share by Region (2024-2034)
Table 11. Drug-Resistant Tuberculosis Treatment Market Trends
Table 12. Drug-Resistant Tuberculosis Treatment Market Drivers
Table 13. Drug-Resistant Tuberculosis Treatment Market Challenges
Table 14. Drug-Resistant Tuberculosis Treatment Market Restraints
Table 15. Global Drug-Resistant Tuberculosis Treatment Revenue by Players (2018-2024) & (US$ Million)
Table 16. Global Drug-Resistant Tuberculosis Treatment Revenue Share by Players (2018-2024)
Table 17. Global Top Drug-Resistant Tuberculosis Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drug-Resistant Tuberculosis Treatment as of 2022)
Table 18. Global Drug-Resistant Tuberculosis Treatment Industry Ranking 2021 VS 2022 VS 2024
Table 19. Global 5 Largest Players Market Share by Drug-Resistant Tuberculosis Treatment Revenue (CR5 and HHI) & (2018-2024)
Table 20. Global Key Players of Drug-Resistant Tuberculosis Treatment, Headquarters and Area Served
Table 21. Global Key Players of Drug-Resistant Tuberculosis Treatment, Product and Application
Table 22. Global Key Players of Drug-Resistant Tuberculosis Treatment, Product and Application
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Drug-Resistant Tuberculosis Treatment Market Size by Type (2018-2024) & (US$ Million)
Table 25. Global Drug-Resistant Tuberculosis Treatment Revenue Market Share by Type (2018-2024)
Table 26. Global Drug-Resistant Tuberculosis Treatment Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 27. Global Drug-Resistant Tuberculosis Treatment Revenue Market Share by Type (2024-2034)
Table 28. Global Drug-Resistant Tuberculosis Treatment Market Size by Application (2018-2024) & (US$ Million)
Table 29. Global Drug-Resistant Tuberculosis Treatment Revenue Share by Application (2018-2024)
Table 30. Global Drug-Resistant Tuberculosis Treatment Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 31. Global Drug-Resistant Tuberculosis Treatment Revenue Share by Application (2024-2034)
Table 32. North America Drug-Resistant Tuberculosis Treatment Market Size by Type (2018-2024) & (US$ Million)
Table 33. North America Drug-Resistant Tuberculosis Treatment Market Size by Type (2024-2034) & (US$ Million)
Table 34. North America Drug-Resistant Tuberculosis Treatment Market Size by Application (2018-2024) & (US$ Million)
Table 35. North America Drug-Resistant Tuberculosis Treatment Market Size by Application (2024-2034) & (US$ Million)
Table 36. North America Drug-Resistant Tuberculosis Treatment Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 37. North America Drug-Resistant Tuberculosis Treatment Market Size by Country (2018-2024) & (US$ Million)
Table 38. North America Drug-Resistant Tuberculosis Treatment Market Size by Country (2024-2034) & (US$ Million)
Table 39. Europe Drug-Resistant Tuberculosis Treatment Market Size by Type (2018-2024) & (US$ Million)
Table 40. Europe Drug-Resistant Tuberculosis Treatment Market Size by Type (2024-2034) & (US$ Million)
Table 41. Europe Drug-Resistant Tuberculosis Treatment Market Size by Application (2018-2024) & (US$ Million)
Table 42. Europe Drug-Resistant Tuberculosis Treatment Market Size by Application (2024-2034) & (US$ Million)
Table 43. Europe Drug-Resistant Tuberculosis Treatment Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 44. Europe Drug-Resistant Tuberculosis Treatment Market Size by Country (2018-2024) & (US$ Million)
Table 45. Europe Drug-Resistant Tuberculosis Treatment Market Size by Country (2024-2034) & (US$ Million)
Table 46. China Drug-Resistant Tuberculosis Treatment Market Size by Type (2018-2024) & (US$ Million)
Table 47. China Drug-Resistant Tuberculosis Treatment Market Size by Type (2024-2034) & (US$ Million)
Table 48. China Drug-Resistant Tuberculosis Treatment Market Size by Application (2018-2024) & (US$ Million)
Table 49. China Drug-Resistant Tuberculosis Treatment Market Size by Application (2024-2034) & (US$ Million)
Table 50. Asia Drug-Resistant Tuberculosis Treatment Market Size by Type (2018-2024) & (US$ Million)
Table 51. Asia Drug-Resistant Tuberculosis Treatment Market Size by Type (2024-2034) & (US$ Million)
Table 52. Asia Drug-Resistant Tuberculosis Treatment Market Size by Application (2018-2024) & (US$ Million)
Table 53. Asia Drug-Resistant Tuberculosis Treatment Market Size by Application (2024-2034) & (US$ Million)
Table 54. Asia Drug-Resistant Tuberculosis Treatment Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2034
Table 55. Asia Drug-Resistant Tuberculosis Treatment Market Size by Region (2018-2024) & (US$ Million)
Table 56. Asia Drug-Resistant Tuberculosis Treatment Market Size by Region (2024-2034) & (US$ Million)
Table 57. Middle East, Africa, and Latin America Drug-Resistant Tuberculosis Treatment Market Size by Type (2018-2024) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Drug-Resistant Tuberculosis Treatment Market Size by Type (2024-2034) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Drug-Resistant Tuberculosis Treatment Market Size by Application (2018-2024) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Drug-Resistant Tuberculosis Treatment Market Size by Application (2024-2034) & (US$ Million)
Table 61. Middle East, Africa, and Latin America Drug-Resistant Tuberculosis Treatment Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 62. Middle East, Africa, and Latin America Drug-Resistant Tuberculosis Treatment Market Size by Country (2018-2024) & (US$ Million)
Table 63. Middle East, Africa, and Latin America Drug-Resistant Tuberculosis Treatment Market Size by Country (2024-2034) & (US$ Million)
Table 64. Sanofi Company Details
Table 65. Sanofi Business Overview
Table 66. Sanofi Drug-Resistant Tuberculosis Treatment Product
Table 67. Sanofi Revenue in Drug-Resistant Tuberculosis Treatment Business (2018-2024) & (US$ Million)
Table 68. Sanofi Recent Developments
Table 69. Novartis AG Company Details
Table 70. Novartis AG Business Overview
Table 71. Novartis AG Drug-Resistant Tuberculosis Treatment Product
Table 72. Novartis AG Revenue in Drug-Resistant Tuberculosis Treatment Business (2018-2024) & (US$ Million)
Table 73. Novartis AG Recent Developments
Table 74. Endo International plc Company Details
Table 75. Endo International plc Business Overview
Table 76. Endo International plc Drug-Resistant Tuberculosis Treatment Product
Table 77. Endo International plc Revenue in Drug-Resistant Tuberculosis Treatment Business (2018-2024) & (US$ Million)
Table 78. Endo International plc Recent Developments
Table 79. CMP Pharma Company Details
Table 80. CMP Pharma Business Overview
Table 81. CMP Pharma Drug-Resistant Tuberculosis Treatment Product
Table 82. CMP Pharma Revenue in Drug-Resistant Tuberculosis Treatment Business (2018-2024) & (US$ Million)
Table 83. CMP Pharma Recent Developments
Table 84. STI Pharma LLC Company Details
Table 85. STI Pharma LLC Business Overview
Table 86. STI Pharma LLC Drug-Resistant Tuberculosis Treatment Product
Table 87. STI Pharma LLC Revenue in Drug-Resistant Tuberculosis Treatment Business (2018-2024) & (US$ Million)
Table 88. STI Pharma LLC Recent Developments
Table 89. Akorn Incorporated Company Details
Table 90. Akorn Incorporated Business Overview
Table 91. Akorn Incorporated Drug-Resistant Tuberculosis Treatment Product
Table 92. Akorn Incorporated Revenue in Drug-Resistant Tuberculosis Treatment Business (2018-2024) & (US$ Million)
Table 93. Akorn Incorporated Recent Developments
Table 94. Lupin Company Details
Table 95. Lupin Business Overview
Table 96. Lupin Drug-Resistant Tuberculosis Treatment Product
Table 97. Lupin Revenue in Drug-Resistant Tuberculosis Treatment Business (2018-2024) & (US$ Million)
Table 98. Lupin Recent Developments
Table 99. Johnson & Johnson Services Inc. Company Details
Table 100. Johnson & Johnson Services Inc. Business Overview
Table 101. Johnson & Johnson Services Inc. Drug-Resistant Tuberculosis Treatment Product
Table 102. Johnson & Johnson Services Inc. Revenue in Drug-Resistant Tuberculosis Treatment Business (2018-2024) & (US$ Million)
Table 103. Johnson & Johnson Services Inc. Recent Developments
Table 104. Macleods Pharmaceuticals Ltd Company Details
Table 105. Macleods Pharmaceuticals Ltd Business Overview
Table 106. Macleods Pharmaceuticals Ltd Drug-Resistant Tuberculosis Treatment Product
Table 107. Macleods Pharmaceuticals Ltd Revenue in Drug-Resistant Tuberculosis Treatment Business (2018-2024) & (US$ Million)
Table 108. Macleods Pharmaceuticals Ltd Recent Developments
Table 109. Pfizer Inc Company Details
Table 110. Pfizer Inc Business Overview
Table 111. Pfizer Inc Drug-Resistant Tuberculosis Treatment Product
Table 112. Pfizer Inc Revenue in Drug-Resistant Tuberculosis Treatment Business (2018-2024) & (US$ Million)
Table 113. Pfizer Inc Recent Developments
Table 114. Hikma Pharmaceuticals PLC Company Details
Table 115. Hikma Pharmaceuticals PLC Business Overview
Table 116. Hikma Pharmaceuticals PLC Drug-Resistant Tuberculosis Treatment Product
Table 117. Hikma Pharmaceuticals PLC Revenue in Drug-Resistant Tuberculosis Treatment Business (2018-2024) & (US$ Million)
Table 118. Hikma Pharmaceuticals PLC Recent Developments
Table 119. Lannett Company Details
Table 120. Lannett Business Overview
Table 121. Lannett Drug-Resistant Tuberculosis Treatment Product
Table 122. Lannett Revenue in Drug-Resistant Tuberculosis Treatment Business (2018-2024) & (US$ Million)
Table 123. Lannett Recent Developments
Table 124. Mylan N.V. Company Details
Table 125. Mylan N.V. Business Overview
Table 126. Mylan N.V. Drug-Resistant Tuberculosis Treatment Product
Table 127. Mylan N.V. Revenue in Drug-Resistant Tuberculosis Treatment Business (2018-2024) & (US$ Million)
Table 128. Mylan N.V. Recent Developments
Table 129. Teva Pharmaceutical Industries Ltd Company Details
Table 130. Teva Pharmaceutical Industries Ltd Business Overview
Table 131. Teva Pharmaceutical Industries Ltd Drug-Resistant Tuberculosis Treatment Product
Table 132. Teva Pharmaceutical Industries Ltd Revenue in Drug-Resistant Tuberculosis Treatment Business (2018-2024) & (US$ Million)
Table 133. Teva Pharmaceutical Industries Ltd Recent Developments
Table 134. Fresenius Kabi AG Company Details
Table 135. Fresenius Kabi AG Business Overview
Table 136. Fresenius Kabi AG Drug-Resistant Tuberculosis Treatment Product
Table 137. Fresenius Kabi AG Revenue in Drug-Resistant Tuberculosis Treatment Business (2018-2024) & (US$ Million)
Table 138. Fresenius Kabi AG Recent Developments
Table 139. Research Programs/Design for This Report
Table 140. Key Data Information from Secondary Sources
Table 141. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Drug-Resistant Tuberculosis Treatment Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 2. Global Drug-Resistant Tuberculosis Treatment Market Share by Type: 2022 VS 2034
Figure 3. First-Line Anti-TB Drugs Features
Figure 4. Second-Line Anti-TB Drugs Features
Figure 5. Others Features
Figure 6. Global Drug-Resistant Tuberculosis Treatment Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 7. Global Drug-Resistant Tuberculosis Treatment Market Share by Application: 2022 VS 2034
Figure 8. Hospital Pharmacy Case Studies
Figure 9. Online Pharmacy Case Studies
Figure 10. Retail Pharmacy Case Studies
Figure 11. Others Case Studies
Figure 12. Drug-Resistant Tuberculosis Treatment Report Years Considered
Figure 13. Global Drug-Resistant Tuberculosis Treatment Market Size (US$ Million), Year-over-Year: 2018-2034
Figure 14. Global Drug-Resistant Tuberculosis Treatment Market Size, (US$ Million), 2018 VS 2022 VS 2034
Figure 15. Global Drug-Resistant Tuberculosis Treatment Market Share by Region: 2022 VS 2034
Figure 16. Global Drug-Resistant Tuberculosis Treatment Market Share by Players in 2022
Figure 17. Global Top Drug-Resistant Tuberculosis Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drug-Resistant Tuberculosis Treatment as of 2022)
Figure 18. The Top 10 and 5 Players Market Share by Drug-Resistant Tuberculosis Treatment Revenue in 2022
Figure 19. North America Drug-Resistant Tuberculosis Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 20. North America Drug-Resistant Tuberculosis Treatment Market Share by Type (2018-2034)
Figure 21. North America Drug-Resistant Tuberculosis Treatment Market Share by Application (2018-2034)
Figure 22. North America Drug-Resistant Tuberculosis Treatment Market Share by Country (2018-2034)
Figure 23. United States Drug-Resistant Tuberculosis Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 24. Canada Drug-Resistant Tuberculosis Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 25. Europe Drug-Resistant Tuberculosis Treatment Market Size YoY (2018-2034) & (US$ Million)
Figure 26. Europe Drug-Resistant Tuberculosis Treatment Market Share by Type (2018-2034)
Figure 27. Europe Drug-Resistant Tuberculosis Treatment Market Share by Application (2018-2034)
Figure 28. Europe Drug-Resistant Tuberculosis Treatment Market Share by Country (2018-2034)
Figure 29. Germany Drug-Resistant Tuberculosis Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 30. France Drug-Resistant Tuberculosis Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 31. U.K. Drug-Resistant Tuberculosis Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 32. Italy Drug-Resistant Tuberculosis Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 33. Russia Drug-Resistant Tuberculosis Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 34. Nordic Countries Drug-Resistant Tuberculosis Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 35. China Drug-Resistant Tuberculosis Treatment Market Size YoY (2018-2034) & (US$ Million)
Figure 36. China Drug-Resistant Tuberculosis Treatment Market Share by Type (2018-2034)
Figure 37. China Drug-Resistant Tuberculosis Treatment Market Share by Application (2018-2034)
Figure 38. Asia Drug-Resistant Tuberculosis Treatment Market Size YoY (2018-2034) & (US$ Million)
Figure 39. Asia Drug-Resistant Tuberculosis Treatment Market Share by Type (2018-2034)
Figure 40. Asia Drug-Resistant Tuberculosis Treatment Market Share by Application (2018-2034)
Figure 41. Asia Drug-Resistant Tuberculosis Treatment Market Share by Region (2018-2034)
Figure 42. Japan Drug-Resistant Tuberculosis Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 43. South Korea Drug-Resistant Tuberculosis Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 44. China Taiwan Drug-Resistant Tuberculosis Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 45. Southeast Asia Drug-Resistant Tuberculosis Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 46. India Drug-Resistant Tuberculosis Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 47. Australia Drug-Resistant Tuberculosis Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 48. Middle East, Africa, and Latin America Drug-Resistant Tuberculosis Treatment Market Size YoY (2018-2034) & (US$ Million)
Figure 49. Middle East, Africa, and Latin America Drug-Resistant Tuberculosis Treatment Market Share by Type (2018-2034)
Figure 50. Middle East, Africa, and Latin America Drug-Resistant Tuberculosis Treatment Market Share by Application (2018-2034)
Figure 51. Middle East, Africa, and Latin America Drug-Resistant Tuberculosis Treatment Market Share by Country (2018-2034)
Figure 52. Brazil Drug-Resistant Tuberculosis Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 53. Mexico Drug-Resistant Tuberculosis Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 54. Turkey Drug-Resistant Tuberculosis Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 55. Saudi Arabia Drug-Resistant Tuberculosis Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 56. Israel Drug-Resistant Tuberculosis Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 57. GCC Countries Drug-Resistant Tuberculosis Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 58. Sanofi Revenue Growth Rate in Drug-Resistant Tuberculosis Treatment Business (2018-2024)
Figure 59. Novartis AG Revenue Growth Rate in Drug-Resistant Tuberculosis Treatment Business (2018-2024)
Figure 60. Endo International plc Revenue Growth Rate in Drug-Resistant Tuberculosis Treatment Business (2018-2024)
Figure 61. CMP Pharma Revenue Growth Rate in Drug-Resistant Tuberculosis Treatment Business (2018-2024)
Figure 62. STI Pharma LLC Revenue Growth Rate in Drug-Resistant Tuberculosis Treatment Business (2018-2024)
Figure 63. Akorn Incorporated Revenue Growth Rate in Drug-Resistant Tuberculosis Treatment Business (2018-2024)
Figure 64. Lupin Revenue Growth Rate in Drug-Resistant Tuberculosis Treatment Business (2018-2024)
Figure 65. Johnson & Johnson Services Inc. Revenue Growth Rate in Drug-Resistant Tuberculosis Treatment Business (2018-2024)
Figure 66. Macleods Pharmaceuticals Ltd Revenue Growth Rate in Drug-Resistant Tuberculosis Treatment Business (2018-2024)
Figure 67. Pfizer Inc Revenue Growth Rate in Drug-Resistant Tuberculosis Treatment Business (2018-2024)
Figure 68. Hikma Pharmaceuticals PLC Revenue Growth Rate in Drug-Resistant Tuberculosis Treatment Business (2018-2024)
Figure 69. Lannett Revenue Growth Rate in Drug-Resistant Tuberculosis Treatment Business (2018-2024)
Figure 70. Mylan N.V. Revenue Growth Rate in Drug-Resistant Tuberculosis Treatment Business (2018-2024)
Figure 71. Teva Pharmaceutical Industries Ltd Revenue Growth Rate in Drug-Resistant Tuberculosis Treatment Business (2018-2024)
Figure 72. Fresenius Kabi AG Revenue Growth Rate in Drug-Resistant Tuberculosis Treatment Business (2018-2024)
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed